Piper Jaffray Downgrades GPC Biotech (GPCB) to Underperform
More News related to GPCB
- Notable Mergers and Acquisitions of the Day 2/18: GPCB
- GPC Biotech AG (GPCB) To Merge With Agennix
- GPC Biotech AG (GPCB) Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn
- Piper Jaffray Downgrades GPC Biotech (GPCB) to Underperform
- StreetInsider.com Pre-Open Movers 10/31
Piper Jaffray downgrades GPC Biotech (Nasdaq: GPCB) from Outperform to Underperform and reduced its price target from EUR15.40 to EUR2.30. The firm expects GPC Biotech to face numerous challenges in the next year, mainly due to failed further approval of its satraplatin.
GPC Biotech AG is a biopharmaceutical company engaged in the discovery, development and commercialization of new drugs to treat cancer.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
